Cooper MyDay well-positioned to benefit from silicone hydrogel, says Stifel After conducting surveys, Stifel believes that Cooper's MyDay lens is very well-positioned to benefit from demand for daily silicone hydrogel. The firm expects MyDay to gain market share, and predicts that Cooper's revenue growth will accelerate in 2015 and 2016. The firm reiterates a Buy rating on the stock.
K2M, Cooper favorite med tech names in current envirnoment, says Piper Jaffray Piper Jaffray analyst Matt O'Brien said that his favorite names in medical technology given the current environment of broader market weakness are K2M Group (KTWO) and Cooper Companies (COO) given their limited exposure to China and the fact that neither has large exposure to big capital equipment purchases or deferrable procedures nor are they in need of capital. O'Brien has Overweight ratings on both stocks.